Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig

British Journal of Pharmacology
O PiotJ C Blanchard

Abstract

1. The NK1 tachykinin receptor agonists, septide, [Sar9,Met(O2)11]SP and [Pro9]SP produced locomotor hyperactivity (10-20 min) when injected intracerebroventricularly (i.c.v.) in the guinea-pig. The most potent in eliciting this hyperactivity was septide (from 0.63 to 5 micrograms), compared to [Sar9,Met(O2)11]SP, which was active at 2.5 and 5 micrograms and [Pro9]SP which induced a non-significant increase even at 10 micrograms. 2. Wet-dog shakes were elicited by septide, [Sar9,Met(O2)11]SP and [Pro9]SP injected by the i.c.v. route in the guinea-pig. [Sar9,Met(O2)11]SP, active from 0.16 to 2.5 micrograms was more potent than septide (active at 1.25 micrograms) and [Pro9]SP (active at 0.63 micrograms) in eliciting such behaviour. To a lesser extent, grooming was also observed after injection of these agonists. 3. The NK2 tachykinin receptor agonist, [Lys5,MeLeu9,Nle10]NKA(4-10), up to the dose of 10 micrograms i.c.v. had no effect in the guinea-pig. It neither modified locomotor activity nor induced a characteristic behavioural response. At higher doses (20 micrograms), some toxic effects were noted. 4. The NK3 tachykinin receptor agonist, senktide, contrasts with the NK1 receptor agonists in that it elicited only wet-dog shake...Continue Reading

References

Jan 23, 1992·Regulatory Peptides·C A MaggiA Giachetti
Jul 1, 1992·Peptides·I MerchenthalerJ M Conlon
Jan 1, 1991·Annals of the New York Academy of Sciences·C A MaggiA Giachetti
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·T V DamR Quirion
Jan 25, 1991·Science·R M SniderR W Spencer
Dec 1, 1990·Pharmacology, Biochemistry, and Behavior·T SakuradaK Kisara
Mar 1, 1991·Naunyn-Schmiedeberg's Archives of Pharmacology·P A Johnston, L A Chahl
May 17, 1991·European Journal of Pharmacology·B D GitterJ J Howbert
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·C GarretP M Laduron
Jan 1, 1991·Annual Review of Neuroscience·S Nakanishi
Jun 24, 1986·European Journal of Pharmacology·S LavielleJ Glowinski
Aug 27, 1986·Brain Research·P J Elliott, S D Iversen
Jul 1, 1986·Journal of Medicinal Chemistry·R LauferZ Selinger
Jul 1, 1987·Neuropeptides·G DrapeauD Regoli
Jan 1, 1987·Progress in Brain Research·J GlowinskiA Marquet
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·R MatsasA J Turner
Jan 22, 1993·Brain Research·D P Geraghty, E Burcher
Feb 26, 1993·Biochemical and Biophysical Research Communications·F PetitetJ Glowinski

❮ Previous
Next ❯

Citations

Aug 12, 1999·European Journal of Pharmacology·A Saria
Oct 22, 2008·European Journal of Pharmacology·Rebecca E NordquistWill Spooren
Jul 29, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mauricette BroccoMark J Millan
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·S C StoutC B Nemeroff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.